Equities

Tauns Laboratories Inc

  • Add to watchlist
  • Add to portfolio
  • Add an alert
197A:TYO

Tauns Laboratories Inc

Actions
Health CareMedical Equipment and Services
  • Price (JPY)559.00
  • Today's Change-5.00 / -0.89%
  • Shares traded630.60k
  • 1 Year change-5.89%
  • Beta--
Data delayed at least 15 minutes, as of Feb 13 2026 06:30 GMT.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

Tauns Laboratories Inc is a Japan-based company engaged in the business of developing, manufacturing and marketing in vitro diagnostic products and research reagents. The Company operates its business in the in vitro diagnostic products business segment. The Company’s main product is antigen test kit that uses immunochromatography to enable rapid diagnosis at the patient's side without the need for special equipment. The products include ImunoAce Flu, ImunoAce SARSCoV-2 II, ImunoAce SARSCoV-2 Saliva, ImunoAce SARSCoV-2/Flu, ImunoAce Adeno, ImunoAce Strep A Neo, ImunoAce hMPV, ImunoAce Mycopiasma, ImunoAce RSV Neo and ImunoAce Noro.

  • Revenue in JPY (TTM)14.92bn
  • Net income in JPY3.69bn
  • Incorporated2016
  • Employees316.00
  • Location
    Tauns Laboratories Inc761-1, KamishimaIZUNOKUNI-SHI 410-2325JapanJPN
  • Phone+81 558768181
  • Fax+81 558760022
  • Websitehttps://www.tauns.co.jp/
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status
197A:TYO since
announced
Transaction
value
Clairvo Technologies IncDeal completed27 Nov 202527 Nov 2025Deal completed5.67%486.00k
Data delayed at least 15 minutes, as of Feb 13 2026 06:30 GMT.

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Mizuho Medy Co Ltd11.26bn3.43bn33.85bn187.009.881.819.173.01179.80179.80591.12980.860.52251.552.09--15.9027.7417.9633.0669.4474.5130.4336.696.46-------1.4821.77-9.2262.0723.87--
Rion Co Ltd27.94bn2.98bn35.47bn1.01k11.891.078.151.27241.73241.732,267.252,682.200.71751.673.8927,692,170.007.656.578.727.6249.5350.1110.669.273.55--0.0028.398.365.377.829.9520.048.61
Nippon Care Supply Co., Ltd.34.10bn2.17bn39.38bn1.45k17.402.104.221.15139.36139.362,194.671,155.761.26101.8030.3523,453,350.008.007.3711.529.8036.4536.776.356.340.7615--0.091359.8011.9410.8813.573.7013.338.76
Cyberdyne Inc4.11bn-3.00m41.10bn211.00--1.5965.1310.00-0.0142-0.014219.46188.520.08331.607.7019,469,190.00-0.1034-1.36-0.1056-1.3861.0857.96-1.24-20.8013.94--0.0108--0.68919.5960.91---5.51--
Win-Partners Co Ltd87.25bn2.14bn43.71bn630.0018.891.7318.120.50175.8575.853,098.48830.261.8321.984.45138,488,200.004.494.298.527.9211.9812.402.452.591.62--0.0068.005.644.759.981.5233.839.52
France Bed Holdings Co Ltd61.19bn2.72bn46.35bn1.81k18.621.135.820.757571.6571.651,627.811,177.550.90172.946.0633,769,870.004.014.195.055.6555.0053.374.454.781.951,504.330.244146.932.382.93-6.0014.15-2.507.39
Japan Eyewear Holdings Co Ltd17.99bn4.22bn47.64bn580.0011.432.807.952.65172.64172.64736.69704.930.47411.8016.5631,022,410.0011.13--12.75--79.15--23.48--0.785318.060.4966--23.20--80.15------
Medikit Co Ltd23.68bn3.09bn47.64bn989.0014.150.952410.472.01211.98211.981,621.483,149.960.46433.144.1023,940,550.006.075.706.726.3038.5539.3713.0713.845.33--0.000241.813.222.54-1.820.854821.5712.47
Nagaileben Co Ltd16.69bn2.48bn55.36bn501.0022.341.4320.083.3280.6280.62544.001,263.590.38981.324.2033,321,640.005.786.906.137.4339.3743.3514.8418.6810.68--0.0067.123.48-0.097-8.81-5.8216.970.00
TAUNS Laboratories Inc14.92bn3.69bn59.48bn316.0016.463.4213.393.9933.9533.95139.96163.580.37210.91622.1347,226,430.009.20--13.12--64.90--24.72--0.948831.130.56--1.05--9.38------
Kitazato Corp10.98bn3.98bn61.04bn86.0015.323.1414.645.5699.6099.60274.45485.650.57231.838.92--20.77--21.73--66.93--36.29--14.33--0.00--2.20---4.63------
Shofu Inc38.97bn4.25bn64.60bn1.41k15.171.4111.921.66118.98118.981,092.321,279.850.75741.239.8127,577,490.008.287.279.278.2459.4558.4110.949.752.72--0.0032.9910.318.1918.1143.72-3.1930.39
Eiken Chemical Co Ltd41.28bn3.83bn88.43bn702.0022.061.9313.902.14116.07116.071,238.231,326.890.66692.863.2358,797,720.006.197.238.089.1039.6345.179.2910.641.3733.810.064240.761.222.07-15.41-8.8313.8912.05
Data as of Feb 13 2026. Currency figures normalised to Tauns Laboratories Inc's reporting currency: Japanese Yen JPY

Institutional shareholders

1.45%Per cent of shares held by top holders
HolderShares% Held
Sumitomo Mitsui DS Asset Management Co., Ltd.as of 30 Sep 2025714.30k0.69%
Nomura Asset Management Co., Ltd.as of 11 Jun 2025404.20k0.39%
Mellon Investments Corp.as of 06 Feb 2026148.50k0.14%
Dimensional Fund Advisors LPas of 05 Feb 2026101.30k0.10%
Global X Japan Co., Ltd.as of 06 Feb 2026100.20k0.10%
Asset Management One Co., Ltd.as of 31 Dec 202415.00k0.02%
DFA Australia Ltd.as of 30 Nov 20255.50k0.01%
American Century Investment Management, Inc.as of 05 Feb 20264.40k0.00%
Dimensional Fund Advisors Ltd.as of 30 Nov 20254.10k0.00%
More ▼
Data from 31 Dec 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.